Phase I Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] Treatment in Patients With Advanced and/or Metastatic Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2018
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
- 20 Jan 2018 Status changed from recruiting to active, no longer recruiting according to results presented at the 2018 Gastrointestinal Cancers Symposium.
- 17 Dec 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.